Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal

Fineline Cube Jun 12, 2026
Company Deals

Kelun-Biotech Receives USD 89 Million Settlement Payment from Medilink Therapeutics Over ADC Pipeline Out-Licensing Dispute

Fineline Cube Jun 12, 2026
Company Deals

HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies

Fineline Cube Jun 12, 2026
Company Deals

Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline

Fineline Cube Jun 12, 2026
Company Deals

QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug

Fineline Cube Jun 11, 2026
Policy / Regulatory

China’s CDE Releases 107th Batch of Reference Preparations for Generic Drug Consistency Evaluation with 17 New Drugs Added

Fineline Cube Jun 12, 2026
Company Drug

Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC

Fineline Cube Jun 12, 2026
Company Drug

Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria

Fineline Cube Jun 12, 2026
Company Deals

3SBio HK$3.1B Placement Funds R&D Pipeline for 705, 706, 008

Fineline Cube Dec 3, 2025

3SBio Inc. (HKG: 1530) conditionally agreed to place 105,169,500 shares at HK$29.62 per share, raising...

Company Drug

Generate GB-0895 Asthma Phase III Trials to Enroll 1,600 Patients

Fineline Cube Dec 3, 2025

Generate: Biomedicines today announced plans to initiate two global Phase III clinical trials (SOLAIRIA-1 and...

Company Drug

Henlius HLX14 Denosumab Biosimilar NDA Accepted by China CDE

Fineline Cube Dec 3, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that the National Medical Products Administration’s Center for...

Company Deals

New-Radiomedicine Series-D Raises 800M Yuan for Radiopharmaceuticals

Fineline Cube Dec 3, 2025

Chengdu New Radiomedicine Technology Co., Ltd. announced completion of its Series D financing round, raising...

Company Deals Drug

Kura ziftomenib Sale Triggers $135M Kyowa-Kirin Payment

Fineline Cube Dec 3, 2025

Kura Oncology, Inc. (NASDAQ: KURA) announced completion of the first US commercial sale of KOMZIFTI...

Company Medical Device

Roche cobas-liat Whooping-Cough Test Secures FDA Clearance

Fineline Cube Dec 3, 2025

Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its cobas liat system-based point‑of‑care test for whooping...

Company Drug

Henlius HLX37 Bispecific NMPA Approval Targets Advanced Solid Tumors

Fineline Cube Dec 2, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that its self-developed investigational new drug, HLX37 (Recombinant...

Company Drug

Leads-Biolabs LBL047 Bispecific Secures China IND Approval for SLE

Fineline Cube Dec 2, 2025

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that the National Medical Products Administration (NMPA)...

Company Deals

Shanghai Bao Pharma IPO HKEX Raises HK$1 Billion for Biotech Pipeline

Fineline Cube Dec 2, 2025

Shanghai Bao Pharmaceuticals Co., Ltd. (HKG: 2659) successfully listed on the Hong Kong Stock Exchange...

Company Drug

Abbisko ABSK141 KRAS-G12D Inhibitor Secures FDA IND Approval

Fineline Cube Dec 2, 2025

Abbisko Cayman Limited (HKG: 2256) announced that its Investigational New Drug (IND) application for ABSK141,...

Company Drug

AbbVie Rinvoq upadacitinib CDE Priority Review Alopecia Areata China

Fineline Cube Dec 2, 2025

AbbVie (NYSE: ABBV) announced that Rinvoq (upadacitinib) has been included in the priority review list...

Company Drug

Lynk Pharma LNK01006 FDA Approval Targets TYK2 for CNS Diseases

Fineline Cube Dec 2, 2025

Lynk Pharmaceuticals Co., Ltd. announced that its self‑developed TYK2 allosteric inhibitor LNK01006 has received FDA...

Others

FDA Prasad Outlines New Vaccine Approval Process After Covid-19 Safety Analysis

Fineline Cube Dec 2, 2025

Dr. Vinay Prasad, FDA’s chief medical and scientific officer, announced plans to overhaul the vaccine...

Hospital Policy / Regulatory

China Health: Life Expectancy Hits 79 Years as Hospitals Expand and Expenditure Controlled

Fineline Cube Dec 2, 2025

The National Health Commission released the Statistical Bulletin on China’s Health Undertakings 2024, showing China’s...

Company Drug

CANbridge’s maralixibat Wins Hong Kong Approval for PFIC Cholestatic Pruritus

Fineline Cube Dec 2, 2025

CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that maralixibat has been approved by the Department of...

Company Deals

WuXi Biologics CRDMO Qatar MOU Establishes First Middle East Center

Fineline Cube Dec 2, 2025

WuXi Biologics (HKG: 2269) announced it has signed a strategic Memorandum of Understanding (MOU) with...

Company Drug

Johnson & Johnson’s Nipocalimab Secures EU Approval for Myasthenia Gravis

Fineline Cube Dec 2, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission has granted Marketing Authorisation...

Company Deals

Regeneron Tessera Partner on TSRA-196 Gene-Writing Therapy for AATD with $275M Deal

Fineline Cube Dec 2, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Tessera Therapeutics announced a global collaboration to develop and...

Company Deals

ChemPartner and Fosun Pharma Forge CRO-CDMO Alliance to Accelerate Drug Development

Fineline Cube Dec 2, 2025

Shanghai ChemPartner Co., Ltd. (SHE: 300149) and Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG:...

Company Medical Device

Microport’s PulseMagic PFA-Catheter Secures NMPA Approval as First Pressure-Monitoring Device in China

Fineline Cube Dec 1, 2025

Shanghai Microport EP Medtech Co., Ltd (SHA: 688351) announced that its PulseMagic TrueForce Disposable Pressure-Monitoring...

Posts pagination

1 … 89 90 91 … 682

Recent updates

  • Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal
  • Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC
  • Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria
  • China’s CDE Releases 107th Batch of Reference Preparations for Generic Drug Consistency Evaluation with 17 New Drugs Added
  • Takeda’s Zasocitinib Demonstrates Superior Efficacy Over Deucravacitinib in Phase III Psoriasis Trial with 35% PASI 100 Response Rate
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal

Company Drug

Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC

Company Drug

Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria

Policy / Regulatory

China’s CDE Releases 107th Batch of Reference Preparations for Generic Drug Consistency Evaluation with 17 New Drugs Added

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.